Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals
Viruses, 2015 There has been a remarkable transformation in the treatment of chronic hepatitis C in recent years with the development of direct acting antiviral agents targeting virus encoded proteins important for viral replication including NS3/4A, NS5A and NS5B ...
Asma Ahmed, Daniel J. Felmlee
doaj +3 more sources
Direct-acting antivirals for chronic hepatitis C [PDF]
Cochrane Database of Systematic Reviews, 2016 Millions of people worldwide suffer from hepatitis C, which can lead to severe liver disease, liver cancer, and death. Direct-acting antivirals (DAAs) are relatively new and expensive interventions for chronic hepatitis C, and preliminary results suggest that DAAs may eradicate hepatitis C virus (HCV) from the blood (sustained virological response ...
Jakobsen, Janus C. +15 more
openaire +8 more sources
SHARED: An International Collaboration to Unravel Hepatitis C Resistance
Viruses, 2021 The advent of direct-acting antivirals (DAAs) has transformed the treatment landscape of hepatitis C [...]
Anita Y.M. Howe +12 more
doaj +1 more source
Hepatitis C virus resistance to the new direct-acting antivirals [PDF]
, 2016 Introduction: The treatment of hepatitis C virus (HCV) infection has dramatically improved in recent years with the widespread use of interferon-free combination regimens.
Esposito, Isabella +2 more
core +1 more source
Therapeutic Advances Against ZIKV: A Quick Response, a Long Way to Go
Pharmaceuticals, 2019 Zika virus (ZIKV) is a mosquito-borne flavivirus that spread throughout the American continent in 2015 causing considerable worldwide social and health alarm due to its association with ocular lesions and microcephaly in newborns, and Guillain−Barr&
Juan-Carlos Saiz
doaj +1 more source
The occurrence of thrombotic thrombocytopenic purpura during treatment of HCV with direct-acting antiviral agents [PDF]
African Journal of Gastroenterology and Hepatology, 2018 Background and aim Experts have reported thrombocytopenia is linked to chronic liver disease in up to 70% of patients with advanced fibrosis and portal hypertension. The occurrence of thrombotic thrombocytopenic purpura (TTP) with HCV infection is a rare
Amr Hanafy, Waseem Seleem, Salem Mohamed
doaj +1 more source
Microbial translocation and T cell activation are modified by direct-acting antiviral therapy in HCV-infected patients [PDF]
, 2018 BACKGROUND: Microbial translocation from the gut lumen has been involved in the pathogenesis of liver damage in hepatitis C virus (HCV) infection. AIM: To investigate the impact of direct-acting antiviral treatment on microbial translocation and T ...
Baroncelli, Silvia +10 more
core +1 more source
Frontiers in Microbiology, 2023 This article systematically presents the current clinically significant therapeutic developments for the treatment of COVID-19 by providing an in-depth review of molecular mechanisms of action for SARS-CoV-2 antivirals and critically analyzing the ...
Oana Săndulescu +8 more
doaj +1 more source
Neuropsychiatric performance and treatment of hepatitis C with direct-acting antivirals: a prospective study [PDF]
, 2017 Background: Since direct-acting antivirals (DAAs) have been approved for the treatment of hepatitis C virus (HCV) infection, a small series of patients with new-onset neuropsychiatric alterations have been referred to us.
Amodio, Piero +11 more
core +1 more source
Hepatitis C Virus and Hepatocellular Carcinoma: Pathogenetic Mechanisms and Impact of Direct-Acting Antivirals [PDF]
, 2018 INTRODUCTION: Globally, between 64 and 103 million people are chronically infected with Hepatitis C virus (HCV), with more than 4.6 million people in the United States and is associated with more than 15.000 deaths annually.
Petruzziello, Arnolfo +5 more
core +1 more source